☆ 4.6 Review

Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Hematology

CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

Astrid Wintering et al.

BLOOD ADVANCES (2023)

Add to Collection

Article Oncology

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial

Theodore W. Laetsch et al.

Summary: Clinical trials often have multiple endpoints with different maturity times. Clinical Trial Updates provide an opportunity to publish additional results beyond the initial report based on the primary endpoint. This update on the ELIANA trial demonstrates the long-term efficacy, safety, and quality of life improvements in pediatric and young adult patients with R/R B-ALL treated with tisagenlecleucel.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Letter Hematology

The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse

Vaibhav Agrawal et al.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy

Allison Barz Leahy et al.

Summary: Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed/refractory B-acute lymphoblastic leukemia (ALL), regardless of different cytogenetic characteristics. High-risk patients, including those with KMT2A-rearranged infant ALL, showed high probabilities of relapse-free survival and overall survival at 2 years.

BLOOD (2022)

Add to Collection

Article Oncology

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

Ibrahim Aldoss et al.

Summary: Blintumomab shows promising activity in relapsed/refractory acute lymphoblastic leukemia (ALL) patients, but there are risk factors for treatment failure, particularly extramedullary relapse and retention of CD19 expression.

CANCER (2022)

Add to Collection

Article Hematology

Outcome of relapsed or refractory acute B-lymphoblastic leukemia patients and BCR-ABL-positive blast cell crisis of B-lymphoid lineage with extramedullary disease receiving inotuzumab ozogamicin

Sabine Kayser et al.

Summary: Inotuzumab ozogamicin appears to be effective in treating relapsed/refractory ALL with extramedullary disease as a debulking strategy. However, inotuzumab ozogamicin followed by allogeneic HSCT seems to be ineffective in maintaining long-term disease control.

HAEMATOLOGICA (2022)

Add to Collection

Article Oncology

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report

Liora M. Schultz et al.

Summary: Commercial tisagenlecleucel demonstrates efficacy and tolerability in patients with relapsed and refractory B-ALL. The study finds that high disease burden is associated with inferior overall survival, event-free survival, and increased toxicity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Regina M. Myers et al.

Summary: This retrospective study investigates the impact of CD19-CAR therapy on relapsed or refractory ALL patients, revealing that nonresponse to blinatumomab and high disease burden are associated with worse survival outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Derek P. Wong et al.

Summary: In this study, a BAFF ligand-based CAR-T cell therapy is developed, which can recognize and kill multiple B cell cancers by binding to three different receptors, reducing the risk of antigen escape.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Hematology

Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy

Elizabeth M. Holland et al.

Summary: CAR T cells are effective in eradicating B-cell acute lymphoblastic leukemia (B-ALL) non-CNS extramedullary disease (EMD), although the response may be delayed and suboptimal, especially in cases of multifocal disease. Serial FDG PET/CT scans are necessary for identifying and monitoring non-CNS EMD.

BLOOD ADVANCES (2022)

Add to Collection

Article Oncology

Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia

Xian Zhang et al.

Summary: TP53 mutation and bone marrow blasts > 20% are two independent factors associated with the CR rate. Patients with high tumor burden as well as those with bone marrow blasts < 5% can benefit from consolidative allo-HSCT post-CAR-T therapy.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Hematology

Efficacy and safety of CD19-specific CAR T-cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Yuekun Qi et al.

BLOOD (2022)

Add to Collection

Article Oncology

CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study

Elad Jacoby et al.

Summary: CAR T-cell therapy shows effectiveness in treating relapsed BCP-ALL patients with CNS involvement, but the risk of neurotoxicity and CNS relapse remains.

LEUKEMIA (2022)

Add to Collection

Article Oncology

Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.

Bijal D. Shah et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Letter Oncology

The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia

Dat Ngo et al.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Letter Oncology

Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

Idoroenyi Amanam et al.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Oncology

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

Michael A. Pulsipher et al.

Summary: We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to identify predictive biomarkers for relapse. The results showed that BMNGS-MRD 0 and B-cell recovery were independently associated with relapse, and detectable BMNGS-MRD reliably predicted the risk.

BLOOD CANCER DISCOVERY (2022)

Add to Collection

Article Hematology

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL

Yaqi Zhao et al.

Summary: This study investigated the efficacy of blinatumomab in patients with B-progenitor acute lymphoblastic leukemia (B-ALL) and found that both tumor-intrinsic and -extrinsic factors influence blinatumomab response. CD19 mutations were commonly detected in CD19(-) relapse during blinatumomab treatment, and the identification of the CD19 ex2part splice variant represents a new biomarker predictive of blinatumomab therapy failure.

BLOOD (2021)

Add to Collection

Article Oncology

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia

Wendy Stock et al.

Summary: The study demonstrated that InO was more effective than standard intensive chemotherapy for patients with R/R Ph+ ALL, showing higher rates of complete remission and minimal residual disease negativity, as well as improved hematopoietic stem cell transplantation rates. However, there was no significant benefit in overall survival, and the probability of being event-free at 12 months was higher with InO treatment.

CANCER (2021)

Add to Collection

Article Oncology

Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

Talha Badar et al.

Summary: A study comparing the efficacy of blinatumomab and InO as first or second NA therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia found that the two agents may have comparable efficacy in this setting.

CANCER (2021)

Add to Collection

Meeting Abstract Hematology

Safety and Efficacy of Subcutaneous (SC) Blinatumomab for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

Pilar Martinez Sanchez et al.

BLOOD (2021)

Add to Collection

Meeting Abstract Hematology

Outcomes of Children and Young Adults with Acute Lymphoblastic Leukaemia Administered Inotuzumab Pre CAR-T Therapy

Khushnuma Mullanfiroze et al.

BLOOD (2021)

Add to Collection

Article Oncology

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Stephan Kadauke et al.

Summary: The study evaluated the effectiveness of risk-adapted preemptive tocilizumab treatment in preventing severe cytokine release syndrome after CTL019 therapy, showing a decrease in the expected incidence of grade 4 CRS without impacting the antitumor efficacy of CTL019.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Hagop M. Kantarjian et al.

Summary: Inotuzumab ozogamicin demonstrated superior response rates, minimal/measurable residual disease negativity, longer duration of remission, and better overall survival compared to standard of care in patients with CD22 positivity >= 90%. Patients with CD22 positivity <90% showed higher response rates with inotuzumab ozogamicin therapy, but similar duration of remission and overall survival.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Patrick A. Brown et al.

Summary: In children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

Venetoclax and navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Vinod A. Pullarkat et al.

Summary: In this phase I study, combining venetoclax with low-dose navitoclax and chemotherapy showed good tolerability and promising efficacy in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Responses were observed in patients across histologic and genomic subtypes, even in those who had failed stem cell transplant therapies.

CANCER DISCOVERY (2021)

Add to Collection

Article Hematology

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

Nitin Jain et al.

Summary: The combination of bosutinib with inotuzumab ozogamicin showed promising efficacy and good tolerability in the treatment of relapsed/refractory Philadelphia chromosome positive acute lymphoblastic leukemia and lymphoid blast phase of chronic myeloid leukemia.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Bijal D. Shah et al.

Summary: The ZUMA-3 study evaluated the efficacy and safety of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The treatment showed a high response rate and tolerable safety profile, with revised adverse event management strategies helping to optimize the risk-benefit ratio.

BLOOD (2021)

Add to Collection

Article Biophysics

Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

Talha Badar et al.

Summary: The safety and efficacy of alloHCT consolidation after blinatumomab for relapsed refractory acute lymphocytic leukemia remains uncertain. Our study of 106 patients who received alloHCT post blinatumomab showed a 2-year progression free survival of 48% and overall survival of 58%. Acute and chronic graft-versus-host disease incidences were 9.9% and 34.4% respectively. Overall survival did not significantly differ between patients who achieved complete remission with MRD negative or positive before alloHCT.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Article Oncology

Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia

Elias Jabbour et al.

Summary: The combination of inotuzumab with low-intensity mini-hyper-CVD chemotherapy, with or without blinatumomab, shows sustained efficacy in patients with relapsed/refractory acute lymphoblastic leukemia. Overall response rate was 80%, with 57% achieving complete response, and 83% of responders achieving measurable residual disease negativity. 3-year overall survival rate was 33%, with a higher rate of 55% in patients with CD22 expression >= 70% and without adverse cytogenetics.

CANCER (2021)

Add to Collection

Article Hematology

CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials

Allison Barz Leahy et al.

Lancet Haematology (2021)

Add to Collection

Article Oncology

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Nirali N. Shah et al.

Summary: CD19-CAR T-cell therapy shows high response rates in CAYAs with B-ALL, but high relapse rates. Sequential therapy with CD19.28 zeta-CAR T cells followed by alloHSCT can achieve durable disease control in a sizable fraction of patients.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Letter Oncology

Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT

Haris Ali et al.

LEUKEMIA RESEARCH (2021)

Add to Collection

Article Oncology

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

Max S. Topp et al.

Summary: Blinatumomab as first salvage in patients with r/r BCP ALL showed longer overall survival, higher remission rates, and comparable safety profile compared to second or later salvage. This suggests that using blinatumomab as first salvage may have greater benefit for patients in terms of survival and remission rates. However, the safety profile showed more frequent issues with cytokine release syndrome, febrile neutropenia, and infection in second or later salvage patients.

CANCER MEDICINE (2021)

Add to Collection

Letter Hematology

Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study

Elias Jabbour et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Claire Roddie et al.

Summary: A novel second-generation CD19-CAR therapy (AUT01) has shown promising results in the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL), demonstrating tolerable safety profile, high remission rates, and excellent persistence. This therapy has the potential to become a stand-alone treatment option for r/r adult B-ALL.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

Add to Collection

Article Hematology

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

Ibrahim Aldoss et al.

Summary: A retrospective study on alloHCT outcomes in 108 adult patients with r/r Phneg B-ALL found that conditioning regimen, number of prior therapies, and choice of salvage therapy influenced relapse-free survival, with encouraging outcomes seen in patients receiving blinatumomab or chemotherapy before alloHCT.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

Add to Collection

Article Oncology

Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp et al.

Summary: This study analyzed long-term follow-up data from two clinical trials involving blinatumomab, finding that one-third of patients with relapsed and/or refractory B-cell precursor acute lymphoblastic leukemia achieving a deep response with blinatumomab lived for 3 years or longer. These results suggest that long-term survival is possible after treatment with blinatumomab, with some patients even undergoing stem cell transplantation showing improved survival outcomes.

CANCER (2021)

Add to Collection

Article Oncology

Adhesion of T Cells to Endothelial Cells Facilitates Blinatumomab-Associated Neurologic Adverse Events

Matthias Klinger et al.

CANCER RESEARCH (2020)

Add to Collection

Article Hematology

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Amandeep Salhotra et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Review Hematology

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

Ibrahim Aldoss et al.

BLOOD (2020)

Add to Collection

Article Hematology

Blinatumomab for infant acute lymphoblastic leukemia

Katherine Clesham et al.

BLOOD (2020)

Add to Collection

Letter Oncology

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Elias Jabbour et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Article Hematology

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Talha Badar et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

Nicola Goekbuget et al.

LEUKEMIA & LYMPHOMA (2020)

Add to Collection

Letter Hematology

Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin

Ryan D. Cassaday et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Oncology

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Daniel J. DeAngelo et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Medicine, General & Internal

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Reuben Benjamin et al.

LANCET (2020)

Add to Collection

Article Hematology

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Kevin A. Hay et al.

BLOOD (2019)

Add to Collection

Article Oncology

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study

Hagop M. Kantarjian et al.

CANCER (2019)

Add to Collection

Article Hematology

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia

David Marks et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Hematology

Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Anthony S. Stein et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Hematology

Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation

Arnon Nagler et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Article Oncology

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Amber C. King et al.

LEUKEMIA RESEARCH (2019)

Add to Collection

Article Oncology

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study

Elias J. Jabbour et al.

CANCER (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Sara Ghorashian et al.

NATURE MEDICINE (2019)

Add to Collection

Article Cell Biology

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies

Hong Qin et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Oncology

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment

David Marks et al.

CANCER MEDICINE (2019)

Add to Collection

Meeting Abstract Hematology

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King et al.

BLOOD (2019)

Add to Collection

Meeting Abstract Hematology

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour et al.

BLOOD (2019)

Add to Collection

Article Hematology

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin

Elias Jabbour et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Hematology

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner et al.

BLOOD (2019)

Add to Collection

Meeting Abstract Hematology

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+Acute Leukemia

Anjali S. Advani et al.

BLOOD (2019)

Add to Collection

Article Hematology

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Nicola Goekbuget et al.

BLOOD ADVANCES (2019)

Add to Collection

Editorial Material Hematology

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab

Ibrahim Aldoss et al.

BLOOD (2018)

Add to Collection

Article Hematology

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Goekbuget et al.

BLOOD (2018)

Add to Collection

Article Hematology

Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab

Max S. Topp et al.

BLOOD (2018)

Add to Collection

Review Biophysics

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

Partow Kebriaei et al.

BONE MARROW TRANSPLANTATION (2018)

Add to Collection

Article Oncology

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Hagop Kantarjian et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial

Elias Jabbour et al.

JAMA ONCOLOGY (2018)

Add to Collection

Article Hematology

Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia

Elad Jacoby et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Oncology

Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD, With or Without Blinatumomab, Is Highly Effective in Patients With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage

Elias Jabbour et al.

CANCER (2018)

Add to Collection

Article Hematology

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

Elias Jabbour et al.

AMERICAN JOURNAL OF HEMATOLOGY (2018)

Add to Collection

Article Hematology

Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy

Joshua A. Hill et al.

BLOOD (2018)

Add to Collection

Article Oncology

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults

Kathryn G. Roberts et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

Giovanni Martinelli et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients

J. Pan et al.

LEUKEMIA (2017)

Add to Collection

Article Medicine, General & Internal

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Hagop M. Kantarjian et al.

LANCET HAEMATOLOGY (2017)

Add to Collection

Article Hematology

Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia

Ibrahim Aldoss et al.

AMERICAN JOURNAL OF HEMATOLOGY (2017)

Add to Collection

Letter Hematology

Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy

Estelle Balducci et al.

ANNALS OF HEMATOLOGY (2017)

Add to Collection

Article Hematology

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner et al.

BLOOD (2017)

Add to Collection

Article Hematology

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study

Daniel J. DeAngelo et al.

BLOOD ADVANCES (2017)

Add to Collection

Article Hematology

Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy

Rebecca Gardner et al.

BLOOD (2016)

Add to Collection

Article Oncology

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

Hagop M. Kantarjian et al.

CANCER (2016)

Add to Collection

Article Medicine, Research & Experimental

CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients

Cameron J. Turtle et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

Add to Collection

Article Oncology

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

Arend von Stackelberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Oncology

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

Hagop M. Kantarjian et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Oncology

Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy

Ahmad Rayes et al.

PEDIATRIC BLOOD & CANCER (2016)

Add to Collection

Article Multidisciplinary Sciences

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity

Elad Jacoby et al.

NATURE COMMUNICATIONS (2016)

Add to Collection

Article Hematology

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

Haiying Qin et al.

BLOOD (2015)

Add to Collection

Article Medicine, General & Internal

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W. Lee et al.

LANCET (2015)

Add to Collection

Article Oncology

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Oncology

Characterization of CD22 Expression in Acute Lymphoblastic Leukemia

Nirali N. Shah et al.

PEDIATRIC BLOOD & CANCER (2015)

Add to Collection

Article Hematology

Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Ling Ge et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)

Add to Collection

Article Oncology

Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

Max S. Topp et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Medicine, General & Internal

Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

K. G. Roberts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Oncology

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

Hagop Kantarjian et al.

CANCER (2013)

Add to Collection

Article Oncology

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Hagop Kantarjian et al.

LANCET ONCOLOGY (2012)

Add to Collection

Article Oncology

Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Oncology

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

Sara Raponi et al.

LEUKEMIA & LYMPHOMA (2011)

Add to Collection

Article Hematology

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Albert Oriol et al.

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)

Add to Collection

Article Hematology

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

Adele K. Fielding et al.

BLOOD (2007)

Add to Collection

Article Oncology

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct

P Hoffmann et al.

INTERNATIONAL JOURNAL OF CANCER (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.